Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication June 12, 2015
- Accepted for publication October 1, 2015
- Published online January 4, 2016.
Article Versions
- previous version (October 8, 2015 - 06:07).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Marleen Keyaerts*,1,2,
- Catarina Xavier*,2,
- Johannes Heemskerk1,
- Nick Devoogdt2,3,
- Hendrik Everaert1,
- Chloé Ackaert3,
- Marian Vanhoeij4,
- Francois P. Duhoux5,
- Thierry Gevaert6,
- Philippe Simon7,
- Denis Schallier8,
- Christel Fontaine8,
- Ilse Vaneycken1,2,
- Christian Vanhove9,
- Jacques De Greve8,
- Jan Lamote4,
- Vicky Caveliers1,2 and
- Tony Lahoutte1,2
- 1Nuclear Medicine Department, UZ Brussel, Brussels, Belgium
- 2In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium
- 3Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium
- 4Department of Oncological Surgery, UZ Brussel, Brussels, Belgium
- 5Medical Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium
- 6Department of Radiation Therapy, UZ Brussel, Brussels, Belgium
- 7Gynecology Senology, Université Libre de Bruxelles Hôpital Erasme, Brussels, Belgium
- 8Department of Medical Oncology, UZ Brussel, Brussels, Belgium; and
- 9Infinity Laboratory, MEDISIP, IbiTech, Ghent University, and iMinds Medical IT, Ghent, Belgium
- For correspondence or reprints contact: Marleen Keyaerts, Nuclear Medicine, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium. E-mail: marleen.keyaerts{at}vub.ac.be
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Generation of a Synthetic Single Domain Antibody Library for Radiopharmaceutical Ligand Discovery
- Engineered Nanobodies Bind Theranostic Main Group Metals
- Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting
- Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cells
- Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers
- Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma
- Two birds with one stone: human SIRP{alpha} nanobodies for functional modulation and in vivo imaging of myeloid cells
- Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients
- Targeted {alpha}-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
- Targeted {alpha}-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment
- Single-Domain Antibody Theranostics on the Horizon
- Gene prediction in the immunoglobulin loci
- Low Level Whole-Brain Radiation Enhances Theranostic Potential Of Single Domain Antibody Fragments For HER2-Positive Brain Metastases
- Sensitizing solid tumors to CAR-mediated cytotoxicity using synthetic antigens
- Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade
- Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment
- Converting an Anti-Mouse CD4 Monoclonal Antibody into an scFv Positron Emission Tomography Imaging Agent for Longitudinal Monitoring of CD4+ T Cells
- Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
- Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer
- Quo Vadis, Molecular Imaging?
- A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential
- Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis
- Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer
- QnAs with Hidde L. Ploegh
- 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
- Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
- A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
- PET Imaging of Receptor Tyrosine Kinases in Cancer
- A Gallium-67/68-Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake
- Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
- First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
- Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
- 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease
- Total-body imaging: Transforming the role of positron emission tomography
- Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
- Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET